Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.

Autor: Nakashima Y; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan., Kondo M; Department of Rheumatology and Orthopaedic Surgery, Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan., Shono E; Department of Rheumatology and Orthopaedic Surgery, Shono Rheumatology Clinic, Fukuoka, Japan., Ishinishi T; Department of Orthopaedic Surgery, Ishinishi Orthopedic Clinic, Fukuoka, Japan., Tsukamoto H; Department of Rheumatology, Shinkokura Hospital, Fukuoka, Japan., Kuroda K; Department of Orthopaedic Surgery, Kuroda Orthopedic Hospital, Fukuoka, Japan., Maeyama A; Department of Orthopedic Surgery, Fukuoka University, Fukuoka, Japan., Harada H; Department of Orthopaedic Surgery, Yagi Hospital, Fukuoka, Japan., Maekawa M; Department of Rheumatology and Orthopaedic Surgery, Maekawa Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan., Shimauchi T; Department of Rheumatology, Fukuoka Hoeikai Hospital, Fukuoka, Japan., Nagamine R; Centre of Artificial Joint and Rheumatism, Fukuoka Tokushukai Medical Center, Fukuoka, Japan., Jojima H; Department of Orthopedic Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan., Yoshizawa S; Department of Rheumatology, Hamanomachi Hospital, Fukuoka, Japan., Tsuru T; Department of Rheumatology, PS Clinic, Fukuoka, Japan., Otsuka T; Department of Rheumatology, Munakata Medical Association Hospital, Fukuoka, Japan., Miyahara H; Department of Orthopedics, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan., Suematsu E; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan., Wada K; Department of Orthopaedic Surgery, Wada Orthopaedic Clinic, Fukuoka, Japan., Yoshizawa S; Department of Rheumatology, National Fukuoka Hospital, Fukuoka, Japan., Inoue Y; Department of Rheumatology, Fukuoka Red Cross Hospital, Fukuoka, Japan., Fukuda T; Department of Rheumatology, Koga Hospital 21, Fukuoka, Japan., Ikemura S; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan., Haraguchi A; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: Modern rheumatology [Mod Rheumatol] 2020 Sep; Vol. 30 (5), pp. 807-815. Date of Electronic Publication: 2019 Oct 17.
DOI: 10.1080/14397595.2019.1676369
Abstrakt: Objectives: To investigate the efficacy of suppressing joint destruction with subcutaneous tocilizumab (TCZ-SC) for Japanese rheumatoid arthritis (RA) patients in the real-world clinical setting. Methods: This 1-year prospective, multicenter study included 110 RA patients in whom TCZ-SC was newly initiated. Primary endpoint was the change from baseline in vdH-modified total Sharp score (mTSS) at week 52. Structural remission was defined as yearly mTSS of 0.5 or less. Disease activity was evaluated using the disease activity score (DAS28-ESR) and clinical disease activity index (CDAI). Results: At baseline, the patients' mean age was 58.6 years, and the mean disease duration was 10.6 years. The proportion of patients who were naïve for biologics was 44.5%, and 64.5% concomitantly received methotrexate. The yearly mTSS showed significant improvement from 9.41 before TCZ-SC initiation to -0.15 after 52 weeks. The structural remission rate was 76.1%. After 52 weeks, the DAS28-ESR and CDAI remission rates were 52% and 21%, respectively. Although the previous usage of biologics and baseline disease activity significantly affected the clinical remission, no factors with significant effects on structural remission were identified. Conclusion: These findings support the efficacy of TCZ-SC in suppressing disease activity as well as joint destruction over a 1-year period.
Databáze: MEDLINE
Externí odkaz: